Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 7/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 7/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222544 | 0.87 | CHRNA7 (0.34) | HRH3 | |
| SCHEMBL24854326 | 0.85 | HRH3 (0.37) | HRH3TLR9TLR8TLR7L3MBTL3 | |
| SCHEMBL24726517 | 0.85 | HRH3 (0.40) | OPRM1OPRK1OPRL1HRH3TLR9 | |
| SCHEMBL23384260 | 0.85 | HRH3 (0.40) | HRH3TLR9TLR8TLR7L3MBTL3 | |
| Hydrochloric Acid SCHEMBL1456033 | 0.84 | GNAI3 (0.38) | HRH3 | |
| Hydrochloric Acid SCHEMBL222616 | 0.84 | GNAI3 (0.38) | HRH3 | |
| SCHEMBL3235820 | 0.83 | HRH3 (0.37) | HRH3 | |
| Hydrochloric Acid SCHEMBL3410008 | 0.82 | HRH3 (0.33) | HRH3 | |
| SCHEMBL22456342 | 0.82 | HRH3 (0.41) | HRH3TLR9TLR8TLR7L3MBTL3 | |
| SCHEMBL14453902 | 0.82 | HRH3 (0.41) | HRH3TLR9TLR8TLR7L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | OPRM1 400/4885OPRK1 478/4885OPRL1 736/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | OPRM1 400/4885OPRK1 478/4885OPRL1 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.